StreetInsider.com News Articles

Form 4 Quanterix Corp For: Oct 15 Filed by: Miller Michael Francis

Fri, 16 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261016/27198008.html

Quanterix Corp. (QTRX) PT Raised to $3.50 at TD Cowen

Tue, 13 Oct 2026 09:30:53 -0400

TD Cowen analyst Dan Brennan raised the price target on Quanterix Corp. (NASDAQ: QTRX) to $3.50 (from $3.00) while maintaining a rating.

Quanterix and Innovita win China approval for Alzheimer's blood tests

Wed, 07 Oct 2026 08:03:17 -0400

Quanterix Corporation (NASDAQ: QTRX) and Innovita Biological Technology Co., Ltd. (SSE: 688253) announced that China's National Medical Products Administration (NMPA) has approved Quanterix's HD-X and SR-X instruments, along with four neurology biomarker testing kits, for use in the Chinese market.

The approved biomarker assays target p-Tau 217, GFAP, p-Tau 181, and NfL — proteins associated with Alzheimer's disease pathology, neurodegeneration, and neuroinflammation. The instruments and kits use Quanterix's Single Molecule Array (Simoa) technology, which is designed to detect proteins at concentrations below the limits of conventional immunoassay methods.

The commercialization arrangement between the two companies was initially formed in 2024. Under the

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

Wed, 07 Oct 2026 08:00:00 -0400

NMPA approvals for Quanterix SIMOA® instruments and key neurology biomarker assays advance access to ultra-sensitive blood-based testing in China

BILLERICA, Mass. & BEIJING--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market.

Initially formed in 2024, the commercialization arrangement combines Quanterix’s ultra-sensitive biomarker detection technology with Innovita’s diagnostics development, regulatory and commercialization capabilities in China. Innovita has now received

Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals

Wed, 07 Oct 2026 08:00:00 -0400

NMPA approvals for Quanterix SIMOA® instruments and key neurology biomarker assays advance access to ultra-sensitive blood-based testing in China

Form 4 Quanterix Corp For: Oct 02 Filed by: Magovcevic-Liebisch Ivana

Fri, 02 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261002/27142141.html

Form 4 Quanterix Corp For: Oct 01 Filed by: Mendel Scott

Fri, 02 Oct 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20261002/27142029.html

Form 4 Quanterix Corp For: Oct 01 Filed by: DONNELLY WILLIAM P

Fri, 02 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261002/27141983.html

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Fri, 25 Sep 2026 08:00:00 -0400

Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX) today reported significant progress on the Content Innovation Engine it introduced at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting new updates at the European Society for Spatial Biology (ESSB) September 28-October 1, 2026. This progress underscores Quanterix's growing leadership in spatial biology content, delivering the assays researchers need to do more pivotal work. Built on the integration of Akoya Biosciences' spatial biology platform and

Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026

Fri, 25 Sep 2026 08:00:00 -0400

Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development

Form 4 Quanterix Corp For: Sep 15 Filed by: Gute James Edward Jr.

Thu, 17 Sep 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260917/27076697.html

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 21:00:00 -0400

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the “Inducement Grants”) were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units (“RSUs”) representing 260,315 shares of Quanterix common stock. The Inducement Grants to the other two employees consisted of 365,326 RSUs in the aggregate representing 365,326 shares of Quanterix common stock.

The RSUs vest in

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 16 Sep 2026 21:00:00 -0400

The RSUs vest in

Form 4 Quanterix Corp For: Sep 15 Filed by: Miller Michael Francis

Wed, 16 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260916/27070995.html

Quanterix names former Quest Diagnostics CMO to lead medical affairs

Mon, 14 Sep 2026 08:01:32 -0400

Quanterix Corporation (Nasdaq: QTRX) has appointed Dr. Yuri Fesko as Chief Medical Officer, according to a company press release. Fesko previously served as Chief Medical Officer at Quest Diagnostics, where he oversaw Medical Affairs, Clinical Development, Analytics, and Public Health.

In his new role, Fesko will provide medical and clinical leadership across Quanterix, working with the company's Diagnostics, Scientific, R&D, Regulatory, and Commercial teams. He will be based at Quanterix's headquarters in Billerica, Mass.

Fesko holds a Doctor of Medicine degree from Case Western Reserve University and completed a fellowship at University Hospitals of Cleveland. He is board-certified in Internal Medicine, Hematology,

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

Mon, 14 Sep 2026 08:00:00 -0400

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company’s Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix’s innovative technologies and applications.

“As we prepare for the broader market launch of our Lucent AD® Complete five biomarker test for Alzheimer’s Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

Mon, 14 Sep 2026 08:00:00 -0400

Form S-8 Quanterix Corp

Fri, 11 Sep 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260911/27050280.html

Form 4 Quanterix Corp For: Aug 19 Filed by: Elliott Jeffrey Thomas

Thu, 20 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26957035.html

Form 4 Quanterix Corp For: Aug 19 Filed by: Elliott Jeffrey Thomas

Thu, 20 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26957035.html

Form 4 Quanterix Corp For: Aug 17 Filed by: DONNELLY WILLIAM P

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946926.html

Form 4 Quanterix Corp For: Aug 17 Filed by: DONNELLY WILLIAM P

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946926.html

Form 3 Quanterix Corp For: Aug 17 Filed by: Gute James Edward Jr.

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946928.html

Form 3 Quanterix Corp For: Aug 17 Filed by: Gute James Edward Jr.

Wed, 19 Aug 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260819/26946928.html

Form 4 Quanterix Corp For: Aug 15 Filed by: Miller Michael Francis

Mon, 17 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260817/26938113.html